NCT04369703

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 199 (actual)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.

Detailed description

Patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in EDTA tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the morning following surgery).

Conditions

• Sellar and Suprasellar Masses
• Pituitary Tumor

Timeline

• Start date: 2020-01-28
• Primary completion: 2022-04-29
• Completion: 2022-04-29
• First posted: 2020-04-30
• Last updated: 2022-06-03

Locations

1 site across 1 country: United States